TO COMPARE THE SAFETY & EFFICACY OF AZILSARTAN VERSUS OLMESARTAN AS ADD ON THERAPY TO CHLORTHALIDONE IN COEXISTING HYPERTENSION WITH TYPE-2 DIABETES MELLITUS RANDOMISED CONTROLLED TRIA
Phase 4
- Conditions
- Health Condition 1: E115- Type 2 diabetes mellitus with circulatory complications
- Registration Number
- CTRI/2020/04/024756
- Lead Sponsor
- DR DEEKSHA SHARMA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Willing to give informed consent for the study.
Consenting adult patients of age > 18 yrs of either sex.
Ambulatory patients diagnosed with hypertension with type 2 diabetes mellitus who have blood pressure > 130/80 mmhg on chlorthalidone therapy
Exclusion Criteria
Patients age less than 18 years.
Patients not willing to give written informed consent
Type 1 diabetes mellitus patients
Stage IV chronic kidney disease (GFRâ??<=â??30â??mL/min per 1.73â??m2)
Congestive heart failure NYHA classes II-IV.
Recent major cardiovascular events ( <6 months prior to randomization)
Pregnant and lactating females
Known hypersensitivity to drugs
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method to check safety and efficacy of trial drugs in patients of hypertension with type 2 diabetesTimepoint: Safety and efficacy checked at the end of first, third and sixth month after initiating the treatment
- Secondary Outcome Measures
Name Time Method to check safety and efficacy of trial drugs in patients of hypertension with type 2 diabetesTimepoint: Safety and efficacy checked in 1 3 and 6 month